All of the active B12 group reporting showed reduction in severity of symptoms ranging toothache from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and remedy runny nose; and p = .005 for IgE reductions. In 1992, the toothache above mentioned data from remedy 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied toothache five children remedy with asthma with toothache metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg remedy of oral cyanocobalamin. In four of the five patients toothache treated, bronchospasm did not develop in the second metabisulfite challenge. remedy.